跳至主要内容
临床试验/EUCTR2007-003481-18-BE
EUCTR2007-003481-18-BE进行中(未招募)1 期

PHASE III PROTOCOL COMPARING A MICROFRACTURE TREATMENT TO A CARTIPATCH® CHONDROCYTE GRAFT TREATMENT IN FEMORAL CONDYLE LESIONS - CARTIPATCH vs MICROFRACTURE

TBF0 个研究点目标入组 64 人开始时间: 2008年9月18日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients presenting an osteocartilaginous femoral single lesion, with a traumatic etiology or an osteochondritis dissecans could be included in this trial only if all the following criteria are met:
  • Patients of both sexes, active, between 18 and 45 years.
  • Osteochondritis dissecans, type III or IV following the ICRS classification.
  • Grade 3 or 4 lesion following the ICRS classification.
  • Lesion’s surface (perpendicular measure: L x l) from 2.50 cm2 to 7.00 cm2 measured following debridment during the arthroscopy.
  • Lesion’s depth should not be over 10 mm.
  • Existence of invalidating symptoms, clinically significant (subjective IKDC score lower than 55).
  • No prior surgical treatment of this lesion such as microfracture according to Pridie method or perforation > 4mm validated by MRI and osteochondral autografts or autologous chondrocytes implantation.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • •Pregnant or breast-feeding women. It will then be required for women in age of giving birth to conduct a pregnancy test before recruiting for the study and to take contraception recognized as efficient.
  • Anaphylactic reaction history to gentamicin and amphotericin B.
  • Femoral osteocartilaginous lesion showing a kissing lesion on the tibial plateau or the patella.
  • Knee varus or valgus > 6°
  • Any symptomatic affection of the patella.
  • Existence of an arthrosis, rheumatoid arthritis or any other articular knee affection (meniscal and ligamentary pathology), which, from the surgeon’s opinion, could potentially compromise the evolution of the treatement.
  • Excessive laxity: Lachman higher than 3 (ICRS). History of one or several crossed ligaments rupture without correction (surgery performed more than 1 year before patient inclusion).
  • Meniscal pathology history concerning 2/3 of meniscus without treatment (surgery performed more than 1 year before patient inclusion).
  • Existence of an ulcerous pathology, tuberculosis, a psychiatrically evaluated pathology or a disease requiring a long-term treatment, including drugs acting on the joint or bone metabolism.
  • Patients suffering present and passed bone, cartilage, muscle or adipose tissue cancer.
  • Patients with positive serological tests for HIV, Hepatitis B and C, HTLV and Syphilis.
  • Patients Body Mass Index higher than 30.

研究者

发起方
TBF

相似试验

进行中(未招募)
1 期
PHASE III CLINICAL TRIAL FOR THE EVALUATION OF THE EFFICACY AND SAFETY OF A PARACETAMOL + IBUPROFEN COMBINATION IN PATIENTS WITH mENSTRUAL PAI
EUCTR2018-000138-37-ESaboratorios Farmalíder S.A.480
已完成
3 期
Phase III Comparative Clinical Trial of Treatment Schedules for Oral UFT/LV Therapy as Postoperative Adjuvant Chemotherapy for Stage IIB/III Colorectal Cancercolorectal cancer
JPRN-C000000245Japanese Foundation for Multidisciplinary Treatment of Cancer840
进行中(未招募)
1 期
Comparative study to evaluate two different treatments for severe dry eye disease. Amniotic membrane extract versus autologous serum eyedrops.Severe Dry Eye DiseaseMedDRA version: 17.1 Level: LLT Classification code 10013778 Term: Dry eyes System Organ Class: 100000004853
EUCTR2011-006287-50-ESClínica Universidad de Navarra/Universidad de Navarra50
进行中(未招募)
不适用
Ensayo clínico fase III, de grupos paralelos, randomizado, controlado con placebo, doble ciego y multicéntrico, para evaluar la eficacia y seguridad de la administración de tocilizumab en pacientes diagnosticados de orbitopatía tiroidea (OT) moderada a severa o que amenaza la vista, que no han respondido adecuadamente al tratamiento con pulsos de corticoides.Efficacy and safety of tocilizumab in patients with moderate to severe or sight-threatening TAO, who have poor response to treatment with pulse steroids. Phase III clinical trial, randomized, placebo-controlled, double-blind, parallel groups and multicenter study.orbitopatía tiroidea (OT)MedDRA version: 13Level: LLTClassification code 10057889Term: Oftalmopatía de Graves
EUCTR2010-023841-31-ESDr. Juan Jesús Gómez-Reino Carnota
已完成
3 期
A Controlled Equivalence Trial Comparing SGPF (Ayurvedic/Herbal) to Celecoxib and Glucosamine in Symptomatic OA Knees (NMITLI)
CTRI/2008/091/000063CSIR440